This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Taichi Kuramochi
Head of Biologics Discovery Department at Chugai Pharmaceutical Co., Ltd.


I am the head of the Biologics Discovery Department at Chugai Pharmaceutical. My department creates novel antibody technologies—such as Recycling Antibody® which dissociate from an antigen in acidic conditions within the cell, Sweeping Antibody® that remove antigens from the bloodstream, and bispecific antibodies that can bind to different antigens at the left and right antigen-binding sites. In recent years, we have evolved these technologies, creating proprietary innovations such as Switch-Ig™ and the next-generation bispecific antibody technology Dual-Ig®.

I have been involved in antibody engineering since joining Chugai in 2005. I contributed to a variety of antibody projects, several of which successfully created candidate antibodies that advanced to clinical trials. I developed Fc engineering technologies for enhancing ADCC and ADCP, as well as FcγRIIb-selective binding. I also established a unique antibody engineering platform called COSMO: Comprehensive Substitution for Multidimensional Optimization.

As a unit manager, I oversaw antibody engineering, protein production, protein analysis, and automation. I have also been working closely with CMC to shorten the time to IND submission. Currently, as a department head, I am responsible for managing our entire biologics project portfolio.

Agenda Sessions

  • Sweeping Antibody® to Maximize Therapeutic Potential in Muscle Disease Models